Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

Highlight

• Perioperative toripalimab combined with chemotherapy significantly reduces surgery cancellation rates in patients with stage III resectable NSCLC.
• Improved tumor and lymph node downstaging rates with toripalimab are strongly associated with enhanced event-free survival (EFS).
• Perioperative toripalimab does not increase surgical complications, demonstrating safety comparable to chemotherapy alone.
• Findings support integrating immune checkpoint inhibitors into multimodal treatment for locally advanced NSCLC to optimize surgical and long-term outcomes.

Study Background